{
  "identification": {
    "trialId": "METC 02",
    "open": true,
    "acronym": "KAYRAS",
    "title": "A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer",
    "nctId": "NCT00000002",
    "phase": "1/2"
  },
  "generalEligibility": [
    {
      "references": [
        {
          "id": "I-01",
          "text": "Patient is â‰¥18 years old."
        }
      ],
      "function": {
        "rule": "IS_AT_LEAST_X_YEARS_OLD",
        "parameters": [
          18
        ]
      }
    },
    {
      "references": [
        {
          "id": "I-02",
          "text": "KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer."
        }
      ],
      "function": {
        "rule": "OR",
        "parameters": [
          {
            "rule": "HAS_LOCALLY_ADVANCED_CANCER",
            "parameters": []
          },
          {
            "rule": "HAS_METASTATIC_CANCER",
            "parameters": []
          }
        ]
      }
    },
    {
      "references": [
        {
          "id": "I-03",
          "text": "ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases."
        }
      ],
      "function": {
        "rule": "HAS_ASAT_AND_ALAT_ULN_OF_AT_MOST_X_OR_AT_MOST_Y_WHEN_LIVER_METASTASES_PRESENT",
        "parameters": [
          3,
          5
        ]
      }
    },
    {
      "references": [
        {
          "id": "I-04",
          "text": "Patient has confirmed KRAS G12D mutation"
        }
      ],
      "function": {
        "rule": "MUTATION_IN_GENE_X_OF_ANY_PROTEIN_IMPACTS_Y",
        "parameters": [
          "KRAS",
          "G12D"
        ]
      }
    }
  ],
  "cohorts": [
    {
      "metadata": {
        "cohortId": "A",
        "evaluable": true,
        "open": true,
        "slotsAvailable": true,
        "blacklist": false,
        "description": "Dose expansion - monotherapy - NSCLC"
      },
      "eligibility": [
        {
          "references": [
            {
              "id": "I-02",
              "text": "KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer."
            }
          ],
          "function": {
            "rule": "HAS_PRIMARY_TUMOR_LOCATION_BELONGING_TO_DOID_TERM_X",
            "parameters": [
              "Lung non-small cell carcinoma"
            ]
          }
        }
      ]
    },
    {
      "metadata": {
        "cohortId": "B",
        "evaluable": true,
        "open": true,
        "slotsAvailable": true,
        "blacklist": false,
        "description": "Dose expansion - monotherapy - Colorectum"
      },
      "eligibility": [
        {
          "references": [
            {
              "id": "I-02",
              "text": "KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer."
            }
          ],
          "function": {
            "rule": "HAS_PRIMARY_TUMOR_LOCATION_BELONGING_TO_DOID_TERM_X",
            "parameters": [
              "Colorectal cancer"
            ]
          }
        }
      ]
    }
  ]
}